Thymidine kinase as a biomarker of chemoresistance in epithelial ovarian cancer using the KELIM model
Leon Meglič
BackgroundOvarian cancer (OC) remains the most lethal gynecological malignancy, with platinum sensitivity being a key determinant of treatment outcomes. The KELIM model, derived from CA-125 kinetics, is a promising biomarker for predicting chemosensitivity. Thymidine kinase 1 (TK1), a proliferation marker, has shown relevance in various cancers but its role in chemotherapy response for OC is unclear.MethodsIn this retrospective study, we assessed the association between TK1 protein (TK1p) and en